Profile data is unavailable for this security.
About the company
Rapport Therapeutics, Inc. is a clinical-stage biotechnology company engaged in discovering and developing small-molecule precision medicines for patients with neurological or psychiatric disorders. It has made discoveries related to the function of receptor-associated proteins (RAPs) in the brain. Its RAP technology platform enables a differentiated approach to generate precision small molecule product candidates with the potential to overcome many limitations of conventional neurology drug discovery. Its precision neuroscience pipeline includes its lead investigational drug, RAP-219, designed to achieve neuroanatomical specificity through its selective targeting of a RAP expressed in only discrete regions of the brain. It is pursuing RAP-219 as a treatment for refractory focal epilepsy, bipolar mania and diabetic peripheral neuropathic pain. Additional preclinical and late-stage discovery stage programs are also underway, including targeting chronic pain and hearing disorders.
- Revenue in USD (TTM)0.00
- Net income in USD-97.70m
- Incorporated2022
- Employees69.00
- LocationRapport Therapeutics Inc99 High Street, Suite 2100BOSTON 02110United StatesUSA
- Phone+1 (857) 321-8020
- Fax+1 (302) 655-5049
- Websitehttps://www.rapportrx.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Septerna Inc | 22.05m | -58.81m | 1.18bn | 75.00 | -- | 3.02 | -- | 53.50 | -1.51 | -1.51 | 0.5304 | 8.71 | 0.0565 | -- | 4.98 | 293,933.30 | -15.06 | -- | -16.99 | -- | -- | -- | -266.77 | -- | -- | -- | 0.00 | -- | 611.92 | -- | -12,762.79 | -- | -- | -- |
| Inhibrx Biosciences Inc | 1.40m | -155.09m | 1.19bn | 156.00 | -- | -- | -- | 851.74 | -10.02 | -10.02 | 0.0905 | -- | 0.007 | -- | 4.96 | 8,974.36 | -77.54 | 114.91 | -96.94 | 138.28 | -- | -- | -11,077.57 | 4,710.68 | -- | -199.52 | 0.7307 | -- | -88.89 | -56.75 | 799.19 | -- | 7.49 | -- |
| Zenas Biopharma Inc | 15.00m | -189.90m | 1.25bn | 130.00 | -- | 5.00 | -- | 83.27 | -12.67 | -12.67 | 0.4565 | 4.65 | 0.0414 | -- | -- | 115,384.60 | -52.35 | -- | -60.38 | -- | -- | -- | -1,265.99 | -- | -- | -116.56 | 0.2709 | -- | -90.00 | -- | -322.87 | -- | -- | -- |
| Taysha Gene Therapies Inc | 6.31m | -99.93m | 1.28bn | 73.00 | -- | 5.83 | -- | 202.29 | -0.3328 | -0.3328 | 0.0212 | 0.7995 | 0.0254 | -- | -- | 86,438.36 | -40.23 | -70.59 | -45.55 | -88.39 | -- | -- | -1,583.66 | -2,287.96 | -- | -- | 0.1899 | -- | -46.07 | -- | 19.96 | -- | -- | -- |
| Rapport Therapeutics Inc | 0.00 | -97.70m | 1.32bn | 69.00 | -- | 2.57 | -- | -- | -2.71 | -2.71 | 0.00 | 10.74 | 0.00 | -- | -- | 0.00 | -22.55 | -- | -23.12 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -125.11 | -- | -- | -- |
| Nektar Therapeutics | 62.60m | -120.74m | 1.35bn | 61.00 | -- | 15.33 | -- | 21.56 | -7.93 | -7.93 | 4.10 | 4.33 | 0.2055 | -- | 97.13 | 1,026,230.00 | -37.21 | -35.30 | -47.69 | -39.56 | 87.26 | 75.63 | -181.08 | -323.39 | -- | -8.54 | 0.469 | -- | 9.22 | -3.00 | 56.91 | -- | -43.84 | -- |
| Monte Rosa Therapeutics Inc | 181.54m | 20.95m | 1.38bn | 147.00 | 75.67 | 4.77 | 47.22 | 7.62 | 0.2506 | 0.2506 | 2.20 | 3.98 | 0.4685 | -- | 65.30 | 1,354,761.00 | 5.41 | -33.14 | 6.24 | -39.19 | -- | -- | 11.54 | -563.84 | -- | -- | 0.00 | -- | -- | -- | 46.29 | -- | 23.56 | -- |
| Intellia Therapeutics Inc | 57.53m | -445.81m | 1.39bn | 403.00 | -- | 1.86 | -- | 24.16 | -4.27 | -4.27 | 0.5488 | 6.46 | 0.0548 | -- | 5.78 | 142,749.40 | -42.49 | -33.78 | -46.95 | -37.16 | -- | -- | -774.94 | -790.71 | -- | -- | 0.00 | -- | 59.55 | 6.07 | -7.86 | -- | -3.19 | -- |
| Kodiak Sciences Inc | 0.00 | -217.34m | 1.40bn | 123.00 | -- | 51.25 | -- | -- | -4.12 | -4.12 | 0.00 | 0.447 | 0.00 | -- | -- | 0.00 | -73.58 | -33.79 | -82.91 | -35.95 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 32.36 | -- | -1.75 | -- |
| Azenta Inc | 594.95m | 28.69m | 1.40bn | 3.00k | 48.70 | 0.8171 | 16.41 | 2.36 | 0.6252 | -1.26 | 12.98 | 37.26 | 0.2891 | 4.03 | 4.00 | 198,317.70 | 1.39 | -0.3901 | 1.57 | -0.4328 | 44.59 | 45.32 | 4.82 | -1.73 | 2.61 | -- | 0.00 | -- | 3.55 | 8.85 | 200.38 | -- | -3.24 | -- |
| Trevi Therapeutics Inc | 0.00 | -45.86m | 1.42bn | 26.00 | -- | 7.47 | -- | -- | -0.3713 | -0.3713 | 0.00 | 1.48 | 0.00 | -- | -- | 0.00 | -34.19 | -45.07 | -36.67 | -51.11 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -64.84 | -- | 31.21 | -- |
| AtaiBeckley Inc | 3.02m | -154.19m | 1.44bn | 54.00 | -- | 5.98 | -- | 476.97 | -0.8136 | -0.8136 | 0.0161 | 0.6644 | 0.0138 | -- | 0.3354 | 55,981.48 | -70.56 | -45.69 | -77.07 | -50.03 | -- | -- | -5,104.20 | -2,658.81 | -- | -- | 0.00 | -- | -1.91 | -- | -271.09 | -- | 37.97 | -- |
| Novavax Inc | 1.06bn | 341.75m | 1.46bn | 952.00 | 4.99 | -- | 3.87 | 1.37 | 1.80 | 1.80 | 6.29 | -0.9643 | 0.7362 | 7.87 | 16.49 | 1,118,331.00 | 23.63 | -39.12 | 53.33 | -248.97 | 91.82 | -- | 32.10 | -67.41 | 2.24 | 17.15 | 2.66 | -- | -30.65 | 105.39 | 65.60 | -- | 47.71 | -- |
Data as of Feb 11 2026. Currency figures normalised to Rapport Therapeutics Inc's reporting currency: US Dollar USD
47.55%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Fidelity Management & Research Co. LLCas of 30 Sep 2025 | 6.92m | 14.51% |
| Capital Research & Management Co. (International Investors)as of 30 Sep 2025 | 3.40m | 7.14% |
| Cormorant Asset Management LPas of 30 Sep 2025 | 3.19m | 6.70% |
| Goldman Sachs & Co. LLC (Private Banking)as of 30 Sep 2025 | 1.63m | 3.43% |
| The Vanguard Group, Inc.as of 31 Dec 2025 | 1.60m | 3.35% |
| Baker Bros. Advisors LPas of 30 Sep 2025 | 1.55m | 3.25% |
| BlackRock Fund Advisorsas of 30 Sep 2025 | 1.42m | 2.97% |
| T. Rowe Price Associates, Inc. (IM)as of 30 Sep 2025 | 1.07m | 2.25% |
| Vestal Point Capital LPas of 30 Sep 2025 | 950.00k | 1.99% |
| Polar Capital LLPas of 30 Sep 2025 | 938.95k | 1.97% |
More ▼
Data from 30 Sep 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
